MiMedx Group, Inc. (MDXG) AI Stock Analysis

MiMedx Group, Inc. specializes in the development and distribution of placental tissue allografts across various healthcare sectors. Utilizing its patented and proprietary PURION process, the company processes human placental tissues into allografts that retain natural biological properties and regulatory proteins. Its commercial portfolio includes EpiFix for chronic wounds such as diabetic foot ulcers and venous leg ulcers, and AmnioFix for surgical recovery. Additional offerings include EpiCord, AmnioCord, AMNIOBURN for partial- and full-thickness burns, and lead micronized powder product mdHACM. Headquartered in Marietta, Georgia, MiMedx markets its products primarily across the United States through direct sales representatives, independent agents, and distributors.

Annual revenue grew from $242.0M in FY2021 to $418.6M in FY2025, representing an 11.0% five-year revenue CAGR. Net income improved from -$12.3M in FY2021 to $48.6M in FY2025, while gross margin remained steady, registering at 82.6% in FY2025. Operating cash flow reached $74.0M and free cash flow was $73.0M in FY2025. Over the trailing twelve months, revenue totaled $355.2M with an operating margin of -28.7% and a profit margin of 1.8%. In the latest quarter ended June 30, 2026, quarterly revenue fell 34.7% year-over-year, while quarterly earnings grew 99.5%.

As of June 30, 2026, MiMedx held $135.8M in cash and short-term investments against total debt of $1.5M, leaving net cash of $134.3M. Total assets stood at $281.0M and shareholders' equity was $216.0M, supporting a debt-to-equity ratio of 0.01 and a current ratio of 5.33. During FY2025, capital expenditures were $1.0M and share buybacks totaled $3.1M. Over the past five years, the company's share count increased 30.6%.

At a last close of $4.43, MiMedx has a market cap of $646.5M and an enterprise value of $578.2M. The stock trades at a trailing P/E of 110.8x and an EV/to/EBITDA of 28.3x, both above the median of its US-listed Healthcare peers of 24.6x and 12.0x, respectively. Its price-to-sales multiple of 1.8x is below the peer median of 4.1x. Over the past year, MDXG shares fell 33.2%, trailing the S&P 500 return of 16.8%.

Wall Street coverage includes 4 Strong Buy ratings and 1 Buy rating, with no Hold or Sell recommendations. The mean price target is $7.40, which is 67.0% above the last close of $4.43. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.08 on revenue of $267.0M. For the next fiscal year, 3 analysts project revenue of $323.5M and EPS of $0.14. MiMedx has beaten EPS estimates in 2 of the last 4 quarters, and its next earnings date is October 28, 2026.

This page is an AI-written research summary of MiMedx Group, Inc. (MDXG). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MDXG income statement, MDXG balance sheet, MDXG key metrics, MDXG analyst forecast, MDXG chart. See the MDXG stock overview for the latest quote and news.